an2728 and Eczema

an2728 has been researched along with Eczema* in 5 studies

Reviews

2 review(s) available for an2728 and Eczema

ArticleYear
Diagnosis and Management of Dermatitis, Including Atopic, Contact, and Hand Eczemas.
    The Medical clinics of North America, 2021, Volume: 105, Issue:4

    This is a comprehensive and current guide for the diagnosis, differential diagnosis, treatment, and management of eczematous dermatitis, with a focus on atopic dermatitis, irritant and allergic contact dermatitis, hand dermatitis including recurrent vesicular and hyperkeratotic types, asteatotic dermatitis, and nummular or discoid dermatitis. Diagnostic options highlighted are clinical history, physical examination, and patch testing. Therapeutic options highlighted are moisturizers, topical corticosteroids, topical calcineurin inhibitors, crisaborole, phototherapy, and systemic medications including biologics.

    Topics: Administration, Topical; Adrenal Cortex Hormones; Aged; Biological Products; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Calcineurin Inhibitors; Child; Child, Preschool; Dermatitis, Allergic Contact; Dermatitis, Atopic; Diagnosis, Differential; Eczema; Humans; Infant; Middle Aged; Patch Tests; Phototherapy; Quality of Life

2021
Utility of boron in dermatology.
    The Journal of dermatological treatment, 2020, Volume: 31, Issue:1

    Topics: Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Dermatitis, Atopic; Drug Design; Eczema; Humans; Onychomycosis; Psoriasis; Skin Diseases; Treatment Outcome

2020

Trials

2 trial(s) available for an2728 and Eczema

ArticleYear
Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis.
    The Journal of dermatology, 2023, Volume: 50, Issue:7

    Atopic dermatitis is a chronic inflammatory skin disease with a significant impact on the overall wellbeing of patients and their families. Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor approved for the treatment of mild-to-moderate atopic dermatitis in multiple countries. However, in the key pivotal trials, a low proportion of the overall patient population was Asian, therefore the safety and efficacy of crisaborole in the Asian population with atopic dermatitis remains unclear. CrisADe CLEAR was a multicenter, randomized, double-blind, vehicle-controlled, phase 3 study (NCT04360187) to assess the efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis involving ≥5% treatable body surface area. Patients were randomly assigned 2:1 to receive crisaborole or vehicle twice daily for 28 days. The primary endpoint was percentage change from baseline in the Eczema Area and Severity Index total score at day 29. Additional endpoints were improvement and success per Investigator's Static Global Assessment score at day 29 and change from baseline on the Peak Pruritus Numerical Rating Scale at week 4. Safety was assessed using rates of treatment emergent adverse events, serious adverse events, and clinically significant changes in vital signs and clinical laboratory parameters. Crisaborole-treated patients showed a significantly greater reduction versus vehicle in percentage change from baseline in Eczema Area and Severity Index total score at day 29 (P = 0.0002). Response rates for achievement of Investigator's Static Global Assessment improvement and success at day 29 were significantly higher for patients treated with crisaborole versus vehicle (P = 0.0124 and P = 0.0078, respectively). Crisaborole-treated patients showed a significantly greater reduction versus vehicle in change from baseline on the Peak Pruritus Numerical Rating Scale at week 4 (P = 0.0009). No new safety signals were identified. Treatment with crisaborole was effective and well tolerated in Chinese and Japanese patients with mild-to-moderate atopic dermatitis.

    Topics: Chronic Disease; Dermatitis, Atopic; Double-Blind Method; East Asian People; Eczema; Humans; Ointments; Phosphodiesterase 4 Inhibitors; Pruritus; Severity of Illness Index; Skin Diseases; Treatment Outcome

2023
Evaluating crisaborole as a treatment option for atopic dermatitis.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:9

    Atopic dermatitis (AD) is a chronic and recurrent disease presenting with eczematous lesions and pruritus. It impacts patient and family quality of life, increases morbidity, and accounts for large health-care expenditures. Although nonpharmacologic, topical, and systemic treatments exist, management of AD remains challenging due to limited treatment options. Crisaborole is a topical small molecule inhibitor of phosphodiesterase 4 (PDE4), recently approved for the treatment of AD in the United States. Areas covered: The authors review crisaborole in the management of AD based on Phase II, Phase III, and post-marketing studies. Pharmacologic properties such as chemistry, pharmacokinetics, pharmacodynamics and metabolism are discussed. A PubMed systematic review was augmented with Google Scholar searches via keyword, Medical Subject Headings (MeSH), and Boolean operation searches. Expert opinion: Crisaborole showed modest efficacy in short-term trials, but head-to-head trials with topical corticosteroids and tacrolimus are needed to assess its clinical utility. Since crisaborole is non-steroidal, it may reduce the need for topical corticosteroids and address steroid phobia. However, it is likely to suffer from the same factors contributing to intentional non-adherence in topicals: dissatisfaction with efficacy and inconvenience.

    Topics: Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Dermatitis, Atopic; Double-Blind Method; Eczema; Humans

2019

Other Studies

1 other study(ies) available for an2728 and Eczema

ArticleYear
Is new better than tried and tested? Topical atopic dermatitis treatment in context.
    The British journal of dermatology, 2018, Volume: 178, Issue:3

    Topics: Administration, Topical; Adult; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Child; Dermatitis, Atopic; Eczema; Humans; Tacrolimus

2018